SELNET ALERT 32

Dear SELNET member,

We share with you an update on the approval process of the amendments and new approvals related to the observational study entitled: "**Observational study, for Quality Assessment, of Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary NETWORK (SELNET)**".

Approval of observational study new institutions:

Country	New Institutions	YES, APPROVED	IN PROGRESS	NO, APPROVED
Argentina	4		1	3
Chile	5		2	3
Colombia	6	1	5	0
Ecuador	1		1	0
México	4	1	1	2
Panamá	1		1	0
República Dominicana	1		1	0
Venezuela	2		2	0
Brazil	5		1	4
Perú	1			1
Bolivia	1		1	
Total	**31**	**2**	**16**	**13**

Adoption Amendment Institutions:

Country	Institutions	YES, APPROVED AMENDMENT	IN PROGRESS	NO, AMENDMENT ADOPTED
Argentina	5		2	3
Bolivia	1			1
Brazil	4		2	2
Chile	3	1		2
Colombia	2		1	1
Costa Rica	5			5
France	3			1
Italy	2			2
México	2			2
Panamá	1			1
Paraguay	2			2
Perú	3		1	2
Spain	9		1	8
Swiss	1			1
Uruguay	1		1	
Total	**44**	**1**	**8**	**33**

It is crucial that we move forward with these approvals so that centres can initiate or continue to register sarcoma cases in the Registry.

We strongly encourage all institutions that have not yet completed the approval process to submit the required documentation to their local Ethics Committees and regulatory bodies. Your active participation in completing these steps is essential to the success of our collective effort and to improving sarcoma patient care throughout our region.

Please remember that approval of the observational study at your institution is directly linked to the ability to contribute data to the Registry.

Thank you for your dedication and collaboration.
Let's work together to keep this important project moving forward!

Sincerely,
SELNET Executive Committee

You are receiving this alert as a member of SELNET (Asociación Europea y latinoamericana SELNET para la Investigación en Sarcoma).
If you do not wish to receive the alert periodically, you must unsubscribe from SELNET by communicating your decision to the following e-mail address info@selnetconsortium.org